Published in BMC Infect Dis on March 02, 2004
Differential immune regulation of activated T cells between cutaneous and mucosal leishmaniasis as a model for pathogenesis. Parasite Immunol (2007) 1.25
Clinical manifestations associated with HTLV type I infection: a cross-sectional study. AIDS Res Hum Retroviruses (2007) 1.20
Clinical manifestations in individuals with recent diagnosis of HTLV type I infection. J Clin Virol (2011) 1.02
Brain magnetic resonance imaging white matter lesions are frequent in HTLV-I carriers and do not discriminate from HAM/TSP. AIDS Res Hum Retroviruses (2007) 0.99
Co-infection by human immunodeficiency virus type 1 (HIV-1) and human T cell leukemia virus type 1 (HTLV-1): does immune activation lead to a faster progression to AIDS? BMC Infect Dis (2009) 0.95
Proviral load and immune markers associated with human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Peru. Clin Exp Immunol (2006) 0.94
Levels of serum chemokines discriminate clinical myelopathy associated with human T lymphotropic virus type 1 (HTLV-1)/tropical spastic paraparesis (HAM/TSP) disease from HTLV-1 carrier state. Clin Exp Immunol (2006) 0.93
Neurological Manifestations in Human T-Cell Lymphotropic Virus Type 1 (HTLV-1)-Infected Individuals Without HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis: A Longitudinal Cohort Study. Clin Infect Dis (2015) 0.92
IFN-gamma production in response to Tax 161-233, and frequency of CD4+ Foxp3+ and Lin HLA-DRhigh CD123+ cells, discriminate HAM/TSP patients from asymptomatic HTLV-1-carriers in a Peruvian population. Immunology (2009) 0.91
Influence of HTLV-1 on the clinical, microbiologic and immunologic presentation of tuberculosis. BMC Infect Dis (2012) 0.88
Infective dermatitis has similar immunological features to human T lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesis. Clin Exp Immunol (2009) 0.86
IL-10 produced by CD4+ and CD8+ T cells emerge as a putative immunoregulatory mechanism to counterbalance the monocyte-derived TNF-alpha and guarantee asymptomatic clinical status during chronic HTLV-I infection. Clin Exp Immunol (2007) 0.85
Interferon Beta-1a Improves Urinary Symptoms, Reduces Proviral Load, and Modifies the Immune Response in a Patient with HAM/TSP. Case Rep Neurol Med (2012) 0.83
Immunological and viral features in patients with overactive bladder associated with human T-cell lymphotropic virus type 1 infection. J Med Virol (2012) 0.83
Ascorbic acid has superior ex vivo antiproliferative, cell death-inducing and immunomodulatory effects over IFN-α in HTLV-1-associated myelopathy. PLoS Negl Trop Dis (2012) 0.81
Effect of TNF-α production inhibitors on the production of pro-inflammatory cytokines by peripheral blood mononuclear cells from HTLV-1-infected individuals. Braz J Med Biol Res (2011) 0.80
Evaluation of the microbicidal activity and cytokines/chemokines profile released by neutrophils from HTLV-1-infected individuals. Scand J Immunol (2011) 0.78
Functional activity of monocytes and macrophages in HTLV-1 infected subjects. PLoS Negl Trop Dis (2014) 0.78
Human T lymphotropic virus type 1 (HTLV-1) proviral load induces activation of T-lymphocytes in asymptomatic carriers. BMC Infect Dis (2014) 0.78
CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis. J Neuroinflammation (2014) 0.78
HTLV-1, Immune Response and Autoimmunity. Viruses (2015) 0.77
Human T Lymphotropic Virus Type I (HTLV-I) is a Risk Factor for Coronary Artery Disease. Iran J Basic Med Sci (2013) 0.77
Leukotrienes are upregulated and associated with human T-lymphotropic virus type 1 (HTLV-1)-associated neuroinflammatory disease. PLoS One (2012) 0.76
Tuberculosis incidence in a cohort of individuals infected with human T-lymphotropic virus type 1 (HTLV-1) in Salvador, Brazil. BMC Infect Dis (2016) 0.76
Human T-cell leukemia virus type-I Tax induces the expression of CD83 on T cells. Retrovirology (2015) 0.76
Constitutive release of IFNγ and IL2 from peripheral blood mononuclear cells of rhesus macaques (Macaca mulatta) infected with simian T-lymphotropic virus type 1. Comp Med (2013) 0.76
Association of Sicca Syndrome with Proviral Load and Proinflammatory Cytokines in HTLV-1 Infection. J Immunol Res (2016) 0.75
Cytokine profile and proviral load among Japanese immigrants and non-Japanese infected with HTLV-1 in a non-endemic area of Brazil. PLoS One (2017) 0.75
Treatment of strongyloidiasis in HTLV-1 and Strongyloides stercoralis coinfected patients is associated with increased TNFα and decreased soluble IL2 receptor levels. Trans R Soc Trop Med Hyg (2013) 0.75
Impairment of the humoral and CD4(+) T cell responses in HTLV-1-infected individuals immunized with tetanus toxoid. Hum Immunol (2016) 0.75
Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology (1983) 40.64
Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A (1980) 30.08
Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet (1985) 13.47
Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood (1977) 10.69
HTLV-I associated myelopathy, a new clinical entity. Lancet (1986) 10.49
CD28- T lymphocytes. Antigenic and functional properties. J Immunol (1993) 3.67
Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol (1998) 3.32
Transformation of human umbilical cord blood T cells by human T-cell leukemia/lymphoma virus. Proc Natl Acad Sci U S A (1983) 3.01
In vivo cellular tropism of human T-cell leukemia virus type 1. J Virol (1990) 2.70
Abundant tax protein expression in CD4+ T cells infected with human T-cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes. Blood (2000) 1.87
Large clonal expansions of human virus-specific memory cytotoxic T lymphocytes within the CD57+ CD28- CD8+ T-cell population. Immunology (1999) 1.37
Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial. Neurology (1996) 1.32
Distribution of human T-lymphotropic virus type I among blood donors: a nationwide Brazilian study. Transfusion (1997) 1.32
Immunological studies in tropical spastic paraparesis. Ann Neurol (1990) 1.26
Pathological mechanisms of human T-cell lymphotropic virus type I-associated myelopathy (HAM/TSP). J Neurovirol (2002) 1.22
Cytokine profile and immunomodulation in asymptomatic human T-lymphotropic virus type 1-infected blood donors. J Acquir Immune Defic Syndr (2001) 1.15
HTLV-I specific IFN-gamma+ CD8+ lymphocytes correlate with the proviral load in peripheral blood of infected individuals. J Neuroimmunol (2000) 1.14
Chagasic patients lack CD28 expression on many of their circulating T lymphocytes. Scand J Immunol (1996) 1.14
Cytokine expression in the spinal cord lesions in HTLV-I-associated myelopathy. J Neuropathol Exp Neurol (1994) 1.09
Prospective study of HTLV-I infection in an initially asymptomatic cohort. J Acquir Immune Defic Syndr (1999) 1.09
Elevated levels of interleukin-6 in serum and cerebrospinal fluid of HTLV-I-associated myelopathy/tropical spastic paraparesis. J Neurol Sci (1990) 1.01
Seroepidemiology of human T-cell lymphotropic virus type I/II in northeastern Brazil. J Acquir Immune Defic Syndr (1993) 0.96
Risk factors and cofactors for human T-cell lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Jamaica. Am J Epidemiol (1995) 0.93
Immunopathogenesis of human T cell lymphotropic virus type I-associated myelopathy. Curr Opin Neurol (2001) 0.91
Spontaneous lymphocyte proliferation in vitro characterizes both HTLV-I and HTLV-II infection. J Acquir Immune Defic Syndr (1990) 0.86
New insights into the functionality of a virion-anchored host cell membrane protein: CD28 versus HIV type 1. J Immunol (2002) 0.84
How does interleukin 15 contribute to the pathogenesis of HTLV type 1-associated myelopathy/tropical spastic paraparesis? AIDS Res Hum Retroviruses (2000) 0.83
Cellular immune responses to HTLV-I: immunopathogenic role in HTLV-I-associated neurologic disease. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 0.81
Up-regulation of Th1-type responses in mucosal leishmaniasis patients. Infect Immun (2002) 2.90
Decreased in situ expression of interleukin-10 receptor is correlated with the exacerbated inflammatory and cytotoxic responses observed in mucosal leishmaniasis. Infect Immun (2005) 2.29
Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clin Infect Dis (2007) 2.08
Disseminated leishmaniasis: a new and emerging form of leishmaniasis observed in northeastern Brazil. J Infect Dis (2002) 2.06
Activated inflammatory T cells correlate with lesion size in human cutaneous leishmaniasis. Immunol Lett (2005) 1.94
Enhanced Leishmania braziliensis infection following pre-exposure to sandfly saliva. PLoS Negl Trop Dis (2007) 1.63
Failure of early treatment of cutaneous leishmaniasis in preventing the development of an ulcer. Clin Infect Dis (2002) 1.60
Epidemiologic and immunologic findings for the subclinical form of Leishmania braziliensis infection. Clin Infect Dis (2002) 1.51
Mucosal leishmaniasis: epidemiological and clinical aspects. Braz J Otorhinolaryngol (2008) 1.49
Serial quantitative PCR assay for detection, species discrimination, and quantification of Leishmania spp. in human samples. J Clin Microbiol (2011) 1.48
Botulinum toxin type A for the treatment of the spastic equinus foot in cerebral palsy. Pediatr Neurol (2006) 1.45
Clinical and immunologic evaluation of 31 patients with acute schistosomiasis mansoni. J Infect Dis (2001) 1.44
Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. PLoS Negl Trop Dis (2010) 1.40
IL6 -174 G/C promoter polymorphism influences susceptibility to mucosal but not localized cutaneous leishmaniasis in Brazil. J Infect Dis (2006) 1.38
Monocytes from patients with indeterminate and cardiac forms of Chagas' disease display distinct phenotypic and functional characteristics associated with morbidity. Infect Immun (2004) 1.33
Reappraisal of the immunopathogenesis of disseminated leishmaniasis: in situ and systemic immune response. Trans R Soc Trop Med Hyg (2011) 1.27
Functional IL-10 gene polymorphism is associated with Chagas disease cardiomyopathy. J Infect Dis (2009) 1.26
Current understanding of immunity to Trypanosoma cruzi infection and pathogenesis of Chagas disease. Semin Immunopathol (2012) 1.26
Schistosoma mansoni infection is associated with a reduced course of asthma. J Allergy Clin Immunol (2003) 1.24
Clinical manifestations associated with HTLV type I infection: a cross-sectional study. AIDS Res Hum Retroviruses (2007) 1.20
Current concepts in immunoregulation and pathology of human Chagas disease. Curr Opin Infect Dis (2008) 1.17
Impaired T helper 2 response to aeroallergen in helminth-infected patients with asthma. J Infect Dis (2004) 1.17
Schistosoma mansoni antigens modulate experimental allergic asthma in a murine model: a major role for CD4+ CD25+ Foxp3+ T cells independent of interleukin-10. Infect Immun (2008) 1.16
Disparate immunoregulatory potentials for double-negative (CD4- CD8-) alpha beta and gamma delta T cells from human patients with cutaneous leishmaniasis. Infect Immun (2006) 1.15
Association of type 2 cytokines with hepatic fibrosis in human Schistosoma mansoni infection. Infect Immun (2004) 1.15
IL-17 mediates immunopathology in the absence of IL-10 following Leishmania major infection. PLoS Pathog (2013) 1.15
Trypanosoma cruzi infection induces differential modulation of costimulatory molecules and cytokines by monocytes and T cells from patients with indeterminate and cardiac Chagas' disease. Infect Immun (2007) 1.14
Association of treatment of American cutaneous leishmaniasis prior to ulcer development with high rate of failure in northeastern Brazil. Am J Trop Med Hyg (2009) 1.14
Protective and pathologic immune responses in human tegumentary leishmaniasis. Front Immunol (2012) 1.13
Urodynamic features of the voiding dysfunction in HTLV-1 infected individuals. Int Braz J Urol (2007) 1.12
Interleukin 17 production among patients with American cutaneous leishmaniasis. J Infect Dis (2009) 1.12
Cellular and genetic mechanisms involved in the generation of protective and pathogenic immune responses in human Chagas disease. Mem Inst Oswaldo Cruz (2009) 1.11
Resistance of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis to nitric oxide correlates with disease severity in Tegumentary Leishmaniasis. BMC Infect Dis (2007) 1.11
Epidemiological and clinical changes in American tegumentary leishmaniasis in an area of Leishmania (Viannia) braziliensis transmission over a 20-year period. Am J Trop Med Hyg (2012) 1.11
Influence of helminth infections on the clinical course of and immune response to Leishmania braziliensis cutaneous leishmaniasis. J Infect Dis (2006) 1.11
Human classical monocytes control the intracellular stage of Leishmania braziliensis by reactive oxygen species. J Infect Dis (2014) 1.09
Evidence of in situ cytotoxicity in American cutaneous leishmaniasis. Eur J Dermatol (2002) 1.09
Urinary and sexual manifestations of patients infected by HTLV-I. Clinics (Sao Paulo) (2007) 1.05
17p duplicated Charcot-Marie-Tooth 1A: characteristics of a new population. J Neurol (2005) 1.05
Recent developments leading toward a paradigm switch in the diagnostic and therapeutic approach to human leishmaniasis. Curr Opin Infect Dis (2008) 1.05
Macrophages participate in host protection and the disease pathology associated with Leishmania braziliensis infection. BMC Infect Dis (2012) 1.04
Geographic clustering of leishmaniasis in northeastern Brazil. Emerg Infect Dis (2009) 1.02
Clinical manifestations in individuals with recent diagnosis of HTLV type I infection. J Clin Virol (2011) 1.02
A functional interleukin-1 beta gene polymorphism is associated with chronic periodontitis in a sample of Brazilian individuals. J Periodontal Res (2005) 1.02
CXCR1 and SLC11A1 polymorphisms affect susceptibility to cutaneous leishmaniasis in Brazil: a case-control and family-based study. BMC Med Genet (2010) 0.99
Resistance of Leishmania (Viannia) braziliensis to nitric oxide: correlation with antimony therapy and TNF-alpha production. BMC Infect Dis (2010) 0.97
IFN-γ production to leishmania antigen supplements the leishmania skin test in identifying exposure to L. braziliensis infection. PLoS Negl Trop Dis (2012) 0.97
Characterization of the immune response to Leishmania infantum recombinant antigens. Microbes Infect (2003) 0.97
The cause of urinary symptoms among Human T Lymphotropic Virus Type I (HLTV-I) infected patients: a cross sectional study. BMC Infect Dis (2007) 0.96
High interleukin 17 expression is correlated with better cardiac function in human Chagas disease. J Infect Dis (2012) 0.95
The -2518bp promoter polymorphism at CCL2/MCP1 influences susceptibility to mucosal but not localized cutaneous leishmaniasis in Brazil. Infect Genet Evol (2010) 0.95
Prevalence of erectile dysfunction in HTLV-1-infected patients and its association with overactive bladder. Urology (2010) 0.95
Immunoregulatory mechanisms and CD4-CD8- (double negative) T cell subpopulations in human cutaneous leishmaniasis: a balancing act between protection and pathology. Int Immunopharmacol (2008) 0.95
Urinary symptoms associated with human T-cell lymphotropic virus type I infection: evidence of urinary manifestations in large group of HTLV-I carriers. Urology (2007) 0.95
Immune responses to an inactive vaccine against American cutaneous leishmaniasis together with granulocyte-macrophage colony-stimulating factor. Vaccine (2002) 0.94
Schistosoma mansoni infection modulates the immune response against allergic and auto-immune diseases. Mem Inst Oswaldo Cruz (2004) 0.94
Differential effects of antigens from L. braziliensis isolates from disseminated and cutaneous leishmaniasis on in vitro cytokine production. BMC Infect Dis (2006) 0.94
Wound healing genes and susceptibility to cutaneous leishmaniasis in Brazil. Infect Genet Evol (2012) 0.94
Association between obesity measured by different parameters and severity of psoriasis. Int J Dermatol (2012) 0.94
Is silent aspiration a risk factor for respiratory infection in Parkinson's disease patients? Parkinsonism Relat Disord (2008) 0.94
Silent saliva aspiration in Parkinson's disease. Mov Disord (2010) 0.93
Cutaneous leishmaniasis during pregnancy: exuberant lesions and potential fetal complications. Clin Infect Dis (2007) 0.93
Trypanosoma cruzi-induced activation of functionally distinct αβ and γδ CD4- CD8- T cells in individuals with polar forms of Chagas' disease. Infect Immun (2010) 0.92
IgG isotype profile is correlated with cardiomegaly in Beagle dogs infected with distinct Trypanosoma cruzi strains. Vet Immunol Immunopathol (2008) 0.92
Association between an emerging disseminated form of leishmaniasis and Leishmania (Viannia) braziliensis strain polymorphisms. J Clin Microbiol (2012) 0.92
Botulinum toxin type A for the treatment of the upper limb spasticity after stroke: a meta-analysis. Arq Neuropsiquiatr (2005) 0.92
Does botulinum toxin improve the function of the patient with spasticity after stroke? Arq Neuropsiquiatr (2007) 0.92
Spatial analysis and risk mapping of soil-transmitted helminth infections in Brazil, using Bayesian geostatistical models. Geospat Health (2013) 0.91
Successful treatment of refractory cutaneous leishmaniasis with GM-CSF and antimonials. Am J Trop Med Hyg (2005) 0.91
Type I IFNs stimulate nitric oxide production and resistance to Trypanosoma cruzi infection. J Immunol (2006) 0.91
Flower cells in patients with infective dermatitis associated with HTLV-1. J Clin Virol (2010) 0.91
Evaluation of IFN-gamma and TNF-alpha as immunological markers of clinical outcome in cutaneous leishmaniasis. Rev Soc Bras Med Trop (2002) 0.91
Histopathological outcome of Leishmania major-infected BALB/c mice is improved by oral treatment with N-acetyl-l-cysteine. Immunology (2003) 0.91
Oxidant generation by single infected monocytes after short-term fluorescence labeling of a protozoan parasite. Infect Immun (2006) 0.91
Zinc/copper imbalance reflects immune dysfunction in human leishmaniasis: an ex vivo and in vitro study. BMC Infect Dis (2004) 0.91
Clinical and immunological outcome in cutaneous leishmaniasis patients treated with pentoxifylline. Am J Trop Med Hyg (2014) 0.90